Do You Really Understand the Trend of Hot Molecular Diagnosis Industry?

According to the latest report of Kalorama Information, the molecular diagnosis industry is expected to grow to 10 billion US dollars in 2020; Grand View Research also said that the molecular diagnosis industry will exceed 15 billion by 2025. This attractive prospect has attracted more and more giant enterprises and small companies in this field. 

As we all know, the biggest players in this field include Roche, Qiagen (Candace Flynn), BD, Abbott, and some new players such as Hologic, Grifols and bioMérieux. However, in the past few years, a large number of small companies have gathered in this field to focus on specific technologies or diseases. 

According to the statistical data of CB Insights, the average investment of projects in the field of molecular diagnosis in the world has shown an overall steady upward trend in recent ten years. In the last year, under the influence of epidemic factors, the growth of actual demand greatly catalyzed the warming of capital enthusiasm. 

Trend of global investment in molecular diagnostics in recent 10 years (Source: CB Insights)

As of the first half of 2020, both the average investment and the median investment in the field of molecular diagnosis in the world have increased greatly compared with 2019. The median investment in the field of molecular diagnosis in recent ten years is about 2.75 million US dollars, and the median investment so far in 2020 is far higher than that in any previous year, which is about 10 million US dollars, more than double that in 2019.

The epidemic has made more attention to the development of molecular diagnosis, and the entry of more resources will inevitably inject greater vitality into the development of the whole industry.

Let's look back at China.

Among the 1096 molecular diagnosis related enterprises in China, Beijing occupies 228, and a large number of excellent enterprises gather. Beijing can be regarded as the leading brother of China's molecular diagnosis industry. 

The rapid development of molecular diagnosis in China cannot be separated from the strong support of policies. Since the 11th Five-Year Plan, NSFC has supported the research on a series of molecular targets in the process of disease occurrence and development. In the national "973" program, clinical research related to high-incidence diseases provides creative research in the field of molecular diagnosis, while the national "863" program focuses on the combination of molecular diagnosis with disease prevention and individualized treatment.

At present, the rapid development of molecular diagnosis focuses on DNA and RNA, that is, gene detection, which has expanded from the early application in infectious disease detection to the current individualized diagnosis and treatment of tumors, blood screening, prenatal screening, genetic disease screening, drug metabolism genomics and other fields.

From each subdivision of China's in vitro diagnosis industry, molecular diagnosis is undoubtedly the subdivision with the most attention from the market and the most potential to overtake foreign corners, whether in terms of technology development degree, market potential and growth rate, or in terms of capital and enterprises with some layout and deep cultivation. However, there are some problems and challenges in the molecular diagnosis industry!